No black box warning on record for Paclitaxel

As of the latest FDA labeling reviewed, Paclitaxel (PACLITAXEL) does not carry a black box warning. Standard warnings and precautions still apply — see the full Paclitaxel medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Anaphylaxis and severe hypersensitivity reactions characterized by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in 2 to 4% of patients receiving paclitaxel in clinical trials. Fatal reactions have occurred in patients despite premedication. All patients should be pretreated with corticosteroids, diphenhydramine, and H 2 antagonists. (see

No black box warning on record for Paclitaxel

Other warnings & precautions

WARNINGS Anaphylaxis and severe hypersensitivity reactions characterized by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in 2 to 4% of patients receiving paclitaxel in clinical trials. Fatal reactions have occurred in patients despite premedication. All patients should be pretreated with corticosteroids, diphenhydramine, and H 2 antagonists. (see

Paclitaxel Black Box Warning

No black box warning on record for Paclitaxel

Other warnings & precautions

Paclitaxel Black Box Warning

No black box warning on record for Paclitaxel

Other warnings & precautions